Clinical Trials & Research Studies in United Kingdom(Updated 8/25)

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

NCT01704716

Recruiting

This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunot... Read More

This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunotherapy (R4 randomization - isotretinoin and ch14.18/CHO (Dinutuximab beta, Qarziba ®).), with or without s.c. aldesleukin (IL-2)). Patients diagnosed after the closure of R3 randomization will not be R4 randomized. For these patients the use of ch14.18/CHO antibody is recommended without scIL-2 as continuous infusion as standard of care outside of controlled trials. ch14.18/CHO received marketing authorization by EMA in May 2017 (Qarziba ®). In the induction phase, all patients receive Rapid COJEC following the result of the R3 randomization which was closed on June 8th, 2017 after inclusion of 630 patients as planned. Following induction treatment peripheral blood stem cell harvest (PBSCH) is performed and complete excision of the primary tumour will be attempted. Patients with an inadequate metastatic response to allow BuMel MAT followed by PBSCR at the end of induction should receive 2 TVD (Topotecan, Vincristine, Doxorubicin) cycles. After Rapid COJEC induction, localized patients will proceed to consolidation. Patients aged 12-18 months at diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without segmental chromosomal alterations (SCAs) are thought to have a good prognosis and will stop treatment after induction therapy and surgery to the primary tumour. Consolidation consists of BuMel MAT based on the results of the R1 randomization followed by peripheral blood stem cell rescue (PBSCR) and radiotherapy to the site of the primary tumour. The R2 immunotherapy randomization using ch14.18/CHO as 8 hour infusion on 5 consecutive days ( total dose (100mg/m²) with or without aldesleukin (IL-2) alternated with isotretinoin (13-cis-RA) is closed. The amended R4 immunotherapy randomization using ch14.18/CHO as continuous infusion (total dose 100mg/m² over 10 days) with or without aldesleukin (IL-2) alternated with isotretinoin (13-cis-RA) has accrued according to plan with results pending awaiting data maturity and DMC approval. Read Less

Gender:

ALL

Ages:

Between 1 month and 21 years

Trial Updated:

10/21/2020

Locations: Women and Children´s Hospital, Adelaide, Not set +125 locations

Women and Children´s Hospital, Adelaide, Not set

Lady Cilento Children´s Hospital, Brisbane, Not set

John Hunter Children's Hospital, Newcastle, Not set

Royal Children's Hospital Melbourne, Parkville, Not set

Sydney Children's Hospital, Sydney, Not set

Children´s Hospital Westmead, Westmead, Not set

St. Anna Kinderspital, Vienna, Austra

Univ.-Klinik für Kinder- und Jugendheilkunde Graz, Graz, Not set

Univ.Klinik f. Kinder-u. Jugendheilkunde Innsbruck, Innsbruck, Not set

Landes- Kinderklinik Linz, Linz, Not set

St. Johanns Spital LKH Salzburg, Salzburg, Not set

Cliniques universitaires St-Luc, Brussels, Not set

Hôpital des Enfants, Brussels, Not set

University Hospital Gent, Gent, Not set

UZ Gasthuisberg, Leuven, Not set

CHR Citadelle, Lüttich, Not set

Clinique de l'Espérance, Montegnee, Not set

University Hospital Motol, Prague, Not set

Aarhus Universitetshospital, Aarhus, Not set

National State Hospital, Copenhagen, Not set

University Hospital of Odense, Odense, Not set

Skejby Hospital, Skejby, Not set

Hopital d'Enfants Dijon, Dijon, Not set

CHU de Grenoble, Grenoble, Not set

CHR Pellegrin, Le Pellerin, Not set

Centre Oscar Lambret de Lille, Lille, Not set

Hopitaux de Marseille La Timone, Marseille, Not set

CHR de Nantes, Nantes, Not set

Hôpital Trousseau Paris, Paris, Not set

Institut Curie, Paris, Not set

Hôpital American Memorial Hospital, Reims, Not set

CHU-Saint Etienne, Saint Etienne, Not set

Hôpital de Hautepierre, Strasbourg, Not set

Hôpital D'Enfants de Toulouse, Toulouse, Not set

Institut Gustave Roussy, Villejuif, Not set

"A&P Kyriakou" Children's Hospital, Athens, Not set

Aghia Sophia Children's Hospital, Athens, Not set

MITERA Hospital, Heraklion, Not set

PEPAGNH University Hospital, Heraklion, Not set

Madarász Children Hospital Budapest, Budapest, Not set

Semmelweis University of Budapest, Budapest, Not set

University of Debrecen, Debrecen, Not set

University of Pecs, Pécs, Not set

University of Szeged, Szeged, Not set

Dublin: OLHSC, Dublin, Not set

Rambam Medical Centre, Haifa, Not set

Schneider Children's Medical Center of Israel, Petah Tiqwa, Not set

Sheba Medical Center, Tel Aviv, Not set

Ospedale G. Salesi, Ancona, Not set

Universitŕ degli studi di Bari, Bari, Not set

Ospedali Riuniti, Bergamo, Not set

Ospedale S. Orsola, Bologna, Not set

Ospedale Regionale per le Microcitemie, Cagliari, Not set

Azienda Ospedaliera di Cosenza, Cosenza, Not set

Azienda Ospedaliera A. Meyer, Firenze, Not set

Istituto Giannina Gaslini, Genua, Not set

Istituto Nazionale Tumori di Milano, Milano, Not set

Azienda Ospedal. Univ. di Modena, Modena, Not set

Sec. Univ. degli Studi di Napoli - Policlinico, Napoli, Not set

Clinica di Oncoematologia Pediatrica Padova, Padova, Not set

Ospedale dei Bambini, Palermo, Palermo, Not set

Azienda Ospedaliera Universitaria di Parma-Oncoematologia Pediatrica, Parma, Not set

Policlinico San Matteo, Pavia, Not set

Ospedale Civile Spirito Santo, Pescara, Not set

Ospedale "Infermi ", Rimini, Not set

Policlinico Borgo Roma, Roma, Not set

Ospedale Bambino Gesu, Rome, Not set

Casa Sollievo della Sofferenza, San Giovanni Rotondo, Not set

O.I.R.M. - S. Anna, Torino, Not set

Istituto per l'Infanzia "Burlo Garofolo", Trieste, Not set

Haukeland University Hospital, Bergen, Not set

Rikshospitalet, Oslo, Not set

University Hospital of North-Norway, Tromso, Not set

Medical University of Bialystok, Bialystok, Not set

Medical University of Bydgoszcz, Bydgoszcz, Not set

Childrens' Hospital in Chorzów, Chorzów, Not set

Medical University in Gdansk, Gdansk, Not set

Upper Silesian Centre of Child and Mother's Care, Katowice, Not set

University Children's Hospital, Kraków, Not set

Children's University Hospital in Lublin, Lublin, Not set

University of Medical Sciences Poznan, Poznan, Not set

Institute Mother and Child, Warschau, Not set

Wroclaw Medical University, Wroclaw, Not set

Ipofg-Crl, Lissabon, Not set

University Hospital F. D. Roosevelt, Banská Bystrica, Not set

University Children's Hospital Ljubljana, Ljubljana, Not set

H. General de Alicante, Alicante, Not set

Hospital Vall d'Hebron, Barcelona, Not set

Hospital de Cruces, Bilbao, Not set

Complejo Hospitalario de Jaen, Jaen, Not set

H . Materno-Infantil Teresa Herrera, La Coruna, Not set

H. Monteprincipe, Madrid, Not set

Hospital 12 de Octubre, Madrid, Not set

H Central de Asturias, Oviedo, Not set

H. C. U. de Salamanca, Salamanca, Not set

H. de Donostia Ntra. Sra. de Aranzazu, San Sebastián, Not set

H. General de Galicia, Santiago De Compostela, Not set

Hospital Virgen del Rocio, Sevilla, Not set

Carlos Haya, Valencia, Not set

Hospital Infantil La Fe, Valencia, Not set

H Clinico-Universitario, Zaragoza, Not set

Queen Silvia's Children's Hospital, Göteburg, Not set

Childrens Hospital Linkoping, Linkoping, Not set

University Children's Hospital, Geneva, Not set

CHUV, Lausanne, Not set

Aberdeen: Royal Aberdeen Children's Hospital, Aberdeen, Not set

Royal Belfast Hospital for Sick Children, Belfast, Not set

Birmingham Children's Hospital, Birmingham, Not set

Bristol Royal Hospital for Children, Bristol, Not set

Addenbrooke's NHS Trust, Cambridge, Not set

Llandough Hospital, Cardiff, Not set

Edinburgh Royal Hospital for Sick Children, Edinburgh, Not set

Glasgow Royal Hospital for Sick Children, Glasgow, Not set

Leeds: St James's University Hospital, Leeds, Not set

Leicester Royal Infirmary, Leicester, Not set

Liverpool: Alder Hey Children's Hospital, Liverpool, Not set

Great Ormond Street Hospital, London, Not set

St Bartholomew's Hospital, London, Not set

UCLH University College London Hospital, London, Not set

Royal Manchester Children's Hospital, Manchester, Not set

Newcastle: Royal Victoria Infirmary, Newcastle, Not set

Nottingham: Queen's Medical Centre, Nottingham, Not set

Oxford: John Radcliffe Hospital, Oxford, Not set

Sheffield Children's Hospital, Sheffield, Not set

Southampton General Hospital, Southhampton, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Neuroblastoma

Register for Updates

Learn More ›

COLO-COHORT (Colorectal Cancer Cohort) Study

NCT04185779

Recruiting

This is a cross-sectional study aimed at identifying factors which best predicts patients at high risk of colorectal cancer or colorectal adenomas and to develop a risk prediction model.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/19/2020

Locations: South Tyneside and Sunderland NHS Foundation Trust, South Shields, Tyne And Wear +2 locations

Conditions: Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasm, Predictive Cancer Model, Model

Register for Updates

Learn More ›

The Biomarkers of Neurological Disease in Utero Study

NCT04043572

Recruiting

Anti-epileptic drugs (AEDs) are potent teratogens associated with a spectrum of physical and neurodevelopmental anomalies to the exposed fetus. Particular risks include congenital malformations, impaired motor and cognitive functioning, autism and poorer educational attainment. Fetal exposure to drugs that bind to central nervous system targets as part of their therapeutic effect (e.g. neurotransmitter receptors and neuronal channels) appear to alter brain structure and function in both animal m... Read More

Gender:

FEMALE

Ages:

Between 18 years and 45 years

Trial Updated:

10/07/2020

Locations: Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire

Conditions: Epilepsy, Neurodevelopmental Disorders, Fetal Disease, Teratogenesis

Register for Updates

Learn More ›

Renal Adjuvant MultiPle Arm Randomised Trial

NCT03288532

Recruiting

RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need for adjuvant therapy is most marked in the high risk population where outcomes are predictably poor. However, the risk of recurrence in patients who are of intermediate risk of recurrence is not insignificant. Unfortunately,... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/03/2020

Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +34 locations

Aberdeen Royal Infirmary, Aberdeen, Not set

Ysbyty Gwynedd, Bangor, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Bristol Haematology and Oncology Centre, Bristol, Not set

Addenbrookes Hospital, Cambridge, Not set

Velindre Cancer Centre, Cardiff, Not set

Broomfield Hospital, Chelmsford, Not set

Cheltenham General Hospital, Cheltenham, Not set

Colchester General Hospital, Colchester, Not set

University Hospital Coventry & Warwickshire, Coventry, Not set

Western General Hospital, Edinburgh, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Diana Princess of Wales Hospital, Grimsby, Not set

Castle Hill Hospital, Hull, Not set

Raigmore Hospital, Inverness, Not set

St James University Hospital, Leeds, Not set

Leicester Royal Infirmary, Leicester, Not set

Clatterbridge Cancer Centre, Liverpool, Not set

St Bartholomew's Hospital, London, Not set

Mount Vernon Hospital, London, Not set

Royal Free Hospital, London, Not set

Guy's Hospital, London, Not set

Royal Marsden Hospital, London, Not set

Charing Cross Hospital, London, Not set

The Christie, Manchester, Not set

Nottingham University Hospital, Nottingham, Not set

Churchill Hospital, Oxford, Not set

Glan Clwyd Hospital, Rhyl, Not set

Scunthorpe General Hospital, Scunthorpe, Not set

Weston Park Hospital, Sheffield, Not set

South Tyneside District Hospital, South Shields, Not set

Southend University Hospital, Southend-on-Sea, Not set

Sunderland Royal Hospital, Sunderland, Not set

Royal Marsden Hospital, Sutton, Not set

Torbay Hospital, Torquay, Not set

Conditions: Renal Cell Carcinoma

Register for Updates

Learn More ›

Serial Tumour Biopsies and Blood Biomarkers in Melanoma

NCT04493723

Recruiting

Recent advances in understanding how cancer develops and spreads have led to effective new treatments and improved outcomes for patients with melanoma. However, we know that these new treatments do not work for all patients: some do not respond to them and some initially respond but then develop resistance. The overall aim of this study will be to collect tumour biopsies, biomarkers present in the blood, and other biological specimens which can be used to try to understand why resistance to anti... Read More

Gender:

ALL

Ages:

16 years and above

Trial Updated:

07/29/2020

Locations: The Christie, Manchester, Not set

Conditions: Melanoma

Register for Updates

Learn More ›

Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool

NCT04481646

Recruiting

COVID-19 has become a global problem. There is an urgent need to improve the diagnosis and screening of patients and healthcare workers for COVID-19 in the UK. Mask based sampling is a method of detecting SARS-COV-2 (the virus responsible for COVID-19) in the breath of suspected COVID-19 patients or healthcare workers in the mask that they would wear in hospital. The investigators have previously demonstrated the utility of this method in other respiratory infections, such as tuberculosis. This... Read More

Gender:

ALL

Ages:

16 years and above

Trial Updated:

07/21/2020

Locations: University Hospitals of Leicester NHS Trust, Leicester, Not set

Conditions: Covid19

Register for Updates

Learn More ›

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

NCT03506997

Recruiting

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

Gender:

MALE

Ages:

18 years and above

Trial Updated:

07/21/2020

Locations: The Royal Marsden Hospital, Sutton, Surrey

Conditions: Castration-resistant Prostate Cancer

Register for Updates

Learn More ›

Liver Disease in Pregnancy

NCT03834285

Recruiting

Liver Diseases in pregnancy represents rare disorders and current data is derived primarily from single centres and retrospective cohorts. Moreover, the population prevalence of these diseases is low and to-date, it has proven difficult to generate reliable data at a patient level. This is a multi-center, prospective cohort study that will open at 3 centers within the UK; and 4 centers in the European Union. The investigators will aim to collect data and blood samples at various time points, fo... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/25/2020

Locations: King's College Hospital NHS Foundation Trust, London, Not set

Conditions: Pregnancy Disease, Cirrhosis, Liver, HELLP Syndrome, AFLP - Acute Fatty Liver of Pregnancy, Intrahepatic Cholestasis of Pregnancy

Register for Updates

Learn More ›

The Harefield Acute Myocardial Infarction Cohort

NCT04218344

Recruiting

In this project the investigator's plan to collect blood during a patient's routine angiogram procedure which they will have due to having suffered a heart attack. Data from the patients' routine procedures for this condition, including but not exclusively, ECG, Echocardiogram, MRI scans, will be collected. The aim of the research project is to analyse the blood samples and identify novel biomarkers and clinical parameters associated with acute coronary syndromes. The investigator's will particu... Read More

Gender:

ALL

Ages:

All

Trial Updated:

01/13/2020

Locations: Harefield Hospital, Harefield, Middlesex +1 locations

Conditions: Acute Coronary Syndrome

Register for Updates

Learn More ›

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

NCT02826863

Recruiting

This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric and young adult subjects with Dravet syndrome. Subjects who qualify for the study will be randomized (1:1:1) in a double-blind manner to receive 1 of 2 doses of ZX008 or placebo. All subjects will be titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects will continue trea... Read More

Gender:

All

Ages:

Between 2 years and 18 years

Trial Updated:

01/02/2020

Locations: Melbourne Brain Centre Austin Hospital, Melbourne, Not set +33 locations

Melbourne Brain Centre Austin Hospital, Melbourne, Not set

Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital, South Brisbane, Not set

The Children's Hospital Westmead Dept. of Neurology and Neurosurgery, Westmead, Not set

Universitair Ziekenhuis Antwerpen, Antwerp, Not set

Danish National Epilepsy Centre, Dianalund, Not set

French Ref centre Necker Hospital Paris, Paris, Not set

Epilepsiezentrum / Neuropädiatrie Hedwig-von-Rittberg-Zentrum Für Kinder und Jugendliche, Berlin, Not set

Krankenhaus Mara Epilepsie-Zentrum Bethel, Bielefeld, Not set

Epilepsiezentrum Freiburg, Freiburg, Not set

Universitaetsklinikum Jena Klinik fuer Kinder- und Jugendmedizin Neuropaediatrie, Jena, Not set

Klinik für Neuropädiatrie Universitätsklinikum Schleswig Holstein Campus Kiel, Kiel, Not set

Kleinwachau Saechsisches Epilepsiezentrum Radeberg gemeinnuetzige GmbH, Radeberg, Not set

Universitaetsklinik fuer Kinder- und Jugendmedizin Abteilung III, Tübingen, Not set

Schoen Klinik Vogtareuth Neuropaediatrie und Neurologische Rehabilitation, Epilepsiezentrum fuer Kinder und Jugendlische, Tagesklinik fuer Neuropaediatrie, Vogtareuth, Not set

AOU Anna Meyer, Firenze, Not set

Istituto Pediatrico Giannina Gaslini Dipartimento di Neurologia, Genova, Not set

A.O Carlo Poma, Mantova, Not set

Instituto Neurologica Carlo Besta, Milano, Not set

Ospedale Fatebenefratelli e Oftalmico, Milano, Not set

U.O. Neurologia Dipartimento di Neuroscienze Ospedale Pediatrico Bambino Gesù, IRCS, Roma, Not set

Ospedal Policlinico Giambattista Rossi diBorga Roma, Verona, Not set

Okayama University Hospital, Okayama-shi, Okayama

Saitama Children's Medical Center, Saitama-shi, Saitama

National Epilepsy Center Shizuoka Institute, Shizuoka-city, Shizuoka

Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo

Hospital Sant Joan de Déu, Barcelona, Not set

Hospital Ruber Internacional Primera Planta Servicio de Neurologia, Madrid, Not set

Clinica Universitaria de Navarra Fase 4. Segunda planta, Consulta de Pediatria, Pamplona, Not set

Birmingham Children Hospital, Birmingham, Not set

Institute of Neurosciences Queens Elizabeth University Hospital, Glasgow, Not set

Alder Hey Hospital, Liverpool, Not set

Evelina Hospital, London, Not set

Great Ormonnd Street Hospital for Children NHS Foundation Trust, London, Not set

Sheffield Children's Hospital, Sheffield, Not set

Conditions: Dravet Syndrome

Register for Updates

Learn More ›

Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

NCT03048942

Recruiting

90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly Paclitaxel to determine the difference in progression free survival between the 2 groups. If results at that stage suggest a potential benefit then the trial will be developed further to accrue 70 more patients.

Gender:

FEMALE

Ages:

Between 18 years and 99 years

Trial Updated:

11/11/2019

Locations: Imperial Healthcare NHS Trust, London, Avon +12 locations

Conditions: HER2 Negative Metastatic Breast Cancer

Register for Updates

Learn More ›

Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment

NCT03727698

Recruiting

The purpose of PERMIT is to collect information on the treatment of radiotherapy patients using a new radiotherapy machine that includes magnetic Resonance (MR) imaging (MR linac) to guide treatment. The aim is to use this information to support the introduction of MR Linac into clinical practice. PERMIT will collect details on patients treated on the MR linac plus details on their side effects and other outcomes. This information plus technical and imaging information will be combined with inf... Read More

Gender:

ALL

Ages:

5 years and above

Trial Updated:

11/06/2019

Locations: Royal Marsden NHSFT, London, Not set

Conditions: Cancer

Register for Updates

Learn More ›

All Clinical Trials in United Kingdom

Match to Clinical Trials